SH2B3 and neoplasm: Silencing Lnk by CRISPR-Cas9 enhanced the tumor-suppressive effect of PD-1 antibody retarding tumor growth, supporting the concept of further exploring the therapeutic potential of targeting LNK plus immune checkpoint therapy.